Off-label use of recombinant activated factor VII - Safe or not safe?

New England Journal of Medicine

Volumn 363, Issue 19, 2010, Pages 1853-1854

  Aledort, Louis M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ARTERY THROMBOSIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG USE; EDITORIAL; HEMOPHILIA; HUMAN; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RISK FACTOR; THROMBOEMBOLISM; THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 78049519509     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1008857     Document Type: Editorial

References (5)

1. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004;2:1700-8.
2. Sallah S, Isaksen M, Seremetis S, Rojkjaer LP. Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs factor VIII inhibitor bypass activity - a rebuttal. J Thromb Haemost 2005;3:820-2.
3. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006;295:293-8.
4. Aledort LM. Recombinant factor VIIa is a pan-hemostatic agent? Thromb Haemost 2000;83:637-8.
5. Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010;363:1791-1800.